Clinical Trial Update: Evaluation of Response of Dasatinib to Treat Mastocytosis [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating dasatinib for systemic mastocytosis; the current update provides no results or status details.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Mastocytosis

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Federico II University | Conditions: Systemic Mastocytosis | Phase 2 | Status: UNKNOWN